12 completed, 3 unknown, 1 withdrawn. 7 Phase 3, 4 Phase 4, 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 6, Unknown 1 |
| Phase 4 | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow 10-valent pneumococcal conjugate vaccine: new trials by email Literature Review of 10-valent pneumococcal conjugate vaccine trials Research Report on 10-valent pneumococcal conjugate vaccine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children PCV10, PCV13 - Pneumonia, Meningitis | Completed | University of Witwatersrand, South Africa | 600 | 2020-02-14 | 2024-08-23 | |
| The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants PCV10, PCV13 - Pneumococcal Infection, Streptococcus Pneumoniae Infection | Phase 4 | Completed | London School of Hygiene and Tropical Medicine | 2100 | 2019-03-21 | 2024-11-12 |
| Reduced PCV Dosing Schedules in South African Infants Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks, Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks, Pneumococcal conjugate vaccine (PCV10 ) 2+1 - Pneumonia, Meningitis | Phase 3 | Completed | University of Witwatersrand, South Africa | 600 | 2017-01-09 | 2019-12-09 |
| Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women PPV-23, PCV-10, NaCl - PNC Vaccine, HIV-infected Pregnant Women | Phase 2 | Completed | Westat | 347 | 2016-03-01 | 2020-01-18 |
| PCV10 Immunogenicity Study Nepal 2015 10-valent pneumococcal conjugate vaccine - Streptococcus Pneumoniae | Phase 4 | Completed | University of Oxford | 304 | 2015-08-21 | 2018-01-11 |
| Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers PATH-wSP, Synflorix, Pentavac - Pneumonia, Pneumococcal | Phase 1 / Phase 2 | Completed | PATH | 304 | 2014-04-01 | 2019-10-10 |
| PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study PCV - Streptococcus Pneumoniae | Unknown | Sheba Medical Center | 12800 | 2014-04-01 | 2017-02-27 | |
| Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam PCV10, PCV13 - Pneumococcal Vaccines | Phase 2 / Phase 3 | Completed | Murdoch Childrens Research Institute | 1400 | 2013-09-30 | 2022-09-14 |
| An Alternative Booster Vaccine Against Meningitis and Ear Infections 13-valent pneumococcal conjugate vaccine, 10-valent pneumococcal conjugate vaccine - Invasive Streptococcus Pneumoniae Disease | Phase 3 | Completed | University of Oxford | 178 | 2012-04-01 | 2015-11-09 |
| Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children Prevenar 13 and Synflorix - Pneumonia, Meningitis | Phase 3 | Unknown | Papua New Guinea Institute of Medical Research | 200 | 2011-11-01 | 2014-03-21 |
| PCV10 Reactogenicity and Immunogenicity Study - Malindi PCV10 and DTaP, hepatitis A vaccine, DTaP, PCV10 - Pneumococcal Pneumonia | Phase 4 | Unknown | KEMRI-Wellcome Trust Collaborative Research Program | 600 | 2010-01-01 | 2018-02-23 |
| Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10 10-valent pneumococcal conjugate vaccine, PCV10 - Pneumococcal Infections | Completed | Finnish Institute for Health and Welfare | 186 | 2009-11-12 | 2021-08-11 | |
| Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine 10 valent pneumococcal conjugate (vaccine) - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 390 | 2006-10-01 | 2016-10-28 |
| Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine. Synflorix, Prevenar, Infanrix hexa - Infections, Streptococcal | Phase 3 | Completed | GlaxoSmithKline | 1200 | 2006-09-25 | 2019-06-10 |
| Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines 10 valent pneumococcal conjugate vaccine, Infanrix Hexa, Rotarix - Infections, Rotavirus | Phase 3 | Completed | GlaxoSmithKline | 400 | 2006-09-01 | 2017-03-23 |
| Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants Synflorix, Prevenar13 - Vaccination, Immunization | Phase 4 | Withdrawn | Public Health England | 2019-08-28 |
Pneumonia (5) · Meningitis (3) · Pneumococcal Infections (3) · Pneumonia, Pneumococcal (2) · Streptococcal Infections (2) · Otitis Media (1) · Rotavirus Infections (1) · Sepsis (1) · Toxemia (1)
GlaxoSmithKline (3) · University of Oxford (2) · University of Witwatersrand, South Africa (2) · Finnish Institute for Health and Welfare (1) · KEMRI-Wellcome Trust Collaborative Research Program (1) · London School of Hygiene and Tropical Medicine (1) · Murdoch Childrens Research Institute (1) · PATH (1) · Papua New Guinea Institute of Medical Research (1) · Public Health England (1) · Sheba Medical Center (1) · Westat (1)
Finland (3) · Kenya (3) · United Kingdom (3) · South Africa (2) · Brazil (1) · Czechia (1) · France (1) · Israel (1) · Papua New Guinea (1) · Poland (1) · Vietnam (1)
Adriana Weinberg, MD (1) · Andrew Pollard (1) · Arto Palmu, MD, PhD (1) · Deborah Lehmann, MSc (1) · Dror Harats, Prof. (1) · Edward K Mulholland, MBBS, FRACP (1) · Elizabeth Coates, PhD (1) · Geraldo Duarte, MD (1) · J. Anthony G Scott, DTMH FMedSci (1) · Laura Hammitt, MD (1) · Marisa Mussi, MD (1) · Nekoye Otsyula, MD (1) · Peter Richmond, MD (1) · Shabir A Madhi, MD PhD (1)
PMID 24465570, PMID 26083474, PMID 29299402, PMID 29329169, PMID 29884695, PMID 30184183, PMID 30635252, PMID 30975525, PMID 32857992, PMID 33745731, PMID 33915104, PMID 34024658, PMID 34171233, PMID 34447389, PMID 34791324, PMID 36785850, PMID 36934731, PMID 37479616, PMID 38637212, PMID 39330966, PMID 39417218, PMID 39865559, PMID 41442837, PMID 42710524